Prescient Therapeutics Ltd

ASX:PTX ISIN:AU000000PTX3

Prescient Therapeutics Limited is a clinical-stage oncology company. The Company's principal activities include in-licensing of intellectual property; the preparation for and conduct of clinical trials relating to the Company's products; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. 
 
           

Lihat di Bahasa Lain

Berita

Laporan Pasar Australia 14 Februari 2011: Black Fire Minerals (ASX:BFE) Akan Mengakuisisi Proyek Tungsten/Tembaga di AS

🕔2/14/2011 12:20:00 PM 28545

Laporan Pasar Australia 14 Februari 2011 memuat: Black Fire Minerals Limited (ASX:BFE) tengah mengakuisisi 100% kepemilikan lanjutan Proyek Tungsten-Tembaga Pilot Mountain di Nevada, Amerika Serikat; Virax Holdings Limited (ASX:VHL) sedang membangun produk untuk pengobatan kanker kulit yang unggu; Southern Cross Goldfields Limited (ASX:SXG) menemukan cadangan emas bermutu tinggi di dekat permukaan di Australia Barat; Prosperity Resources Limited (ASX:PSP) memulai penggalian emas di Indonesia.

Baca Full Story
###

133,990 TAMPILAN PROFIL PERUSAHAAN

  • Halaman ini dilihat: (7 Hari Terakhir: 11) (30 Hari Terakhir: 42) (Sejak Ditampilkan: 10478) 

Data Perusahaan

    Fax
  • (03) 9853 5134 
  • Sektor Utama
  • Kesehatan & Pharm 
  • Industri Utama
  • Biotechnology 
  • Homepage
  • www.virax.com.au/

Lebih banyak Berita lagi

  • 2024/11/14: Results of Annual General Meeting*
  • 2024/11/14: Chair and CEO AGM Presentation*
  • 2024/10/31: September 2024 Quarterly Update and Appendix 4C*
  • 2024/10/14: Notice of Annual General Meeting/Proxy Form*
  • 2024/10/03: Change of Director's Interest Notice*
  • 2024/10/02: Notification of cessation of securities - PTX*
  • 2024/09/12: Prescient CEO to step down in early 2025*
  • 2024/09/05: PTX Presentation*
  • 2024/08/26: Appendix 4G and Corporate Governance Statement*
  • 2024/08/26: Appendix 4E and 2024 Annual Report*
*refer to company website